Advertisement
Screener

GERON CORP (GERN) Income (Loss) from Equity Method Investments

1.5 / 5 stars · 23/76 Roast Me

GERON CORP Income (Loss) from Equity Method Investments

GERON CORP (GERN) reported Income (Loss) from Equity Method Investments of $0 for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-07.

Discontinued › Income Statement › Other Income

us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2014-03-17

  • GERON CORP income (loss) from equity method investments for the quarter ending 2012-03-31 was $0.00.
  • GERON CORP income (loss) from equity method investments for the quarter ending 2011-12-31 was $0.00.
  • GERON CORP income (loss) from equity method investments for the quarter ending 2011-09-30 was $0.00.
  • GERON CORP income (loss) from equity method investments for the quarter ending 2011-06-30 was -$168.00K.
  • GERON CORP income (loss) from equity method investments for fiscal 2011 was -$503.00K.
  • GERON CORP income (loss) from equity method investments for fiscal 2010 was -$2.35M.
  • GERON CORP income (loss) from equity method investments for fiscal 2009 was -$1.34M.
Period endIncome (Loss) from Equity Method Investments 3 monthIncome (Loss) from Equity Method Investments 6 monthIncome (Loss) from Equity Method Investments 9 monthIncome (Loss) from Equity Method Investments 12 month
2012-03-31$0.00
10-Q · filed 2012-05-07
$0.00
derived: sum of 2 quarters · filed 2014-03-17
$0.00
derived: sum of 3 quarters · filed 2014-03-17
-$168.00K
derived: sum of 4 quarters · filed 2014-03-17
2011-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17
$0.00
derived: sum of 2 quarters · filed 2014-03-17
-$168.00K
derived: sum of 3 quarters · filed 2014-03-17
-$503.00K
10-K · filed 2014-03-17
2011-09-30$0.00
10-Q · filed 2011-11-03
-$168.00K
derived: sum of 2 quarters · filed 2012-08-03
-$503.00K
10-Q · filed 2012-11-02
-$1.72M
derived: sum of 4 quarters · filed 2013-03-15
2011-06-30-$168.00K
10-Q · filed 2012-08-03
-$503.00K
10-Q · filed 2012-08-03
-$1.72M
derived: sum of 3 quarters · filed 2013-03-15
-$1.96M
derived: sum of 4 quarters · filed 2013-03-15
2011-03-31-$335.00K
10-Q · filed 2012-05-07
-$1.55M
derived: sum of 2 quarters · filed 2013-03-15
-$1.79M
derived: sum of 3 quarters · filed 2013-03-15
-$2.29M
derived: sum of 4 quarters · filed 2013-03-15
2010-12-31-$1.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15
-$1.46M
derived: sum of 2 quarters · filed 2013-03-15
-$1.95M
derived: sum of 3 quarters · filed 2013-03-15
-$2.35M
10-K · filed 2013-03-15
2010-09-30-$243.00K
10-Q · filed 2011-11-03
-$739.00K
derived: sum of 2 quarters · filed 2011-11-03
-$1.14M
10-Q · filed 2011-11-03
2010-06-30-$496.00K
10-Q · filed 2011-08-05
-$892.00K
10-Q · filed 2011-08-05
2009-12-31-$1.34M
10-K · filed 2012-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
Faeth Therapeutics, Inc. (FTH)United States$0.750B